



September 12, 2024

Company name	CellSource Co., Ltd.
Name of representative	Takashi Sawada, Representative Director and CEO
Securities code	4880, Tokyo Stock Exchange, Prime Market
Contact information for inquiries	Katsuji Onishi, Executive Officer and General Manager of Administration Tel: +81-3-6455-5308

Notice Regarding Acquisition of Medibase as a Wholly Owned Subsidiary Through Share Purchase

We hereby announce that the Board of Directors, at a meeting held on September 12, 2024, resolved to acquire the shares of Medibase Co., Ltd (“Medibase”) to make it a wholly owned subsidiary, as detailed below (hereinafter referred to as the “Transaction”).

1. Purpose of the Transaction

We primarily offer services that involve processing cells and blood used in regenerative medicine, outsourced from medical institutions, in the self-funded medical fields such as orthopedic surgery, obstetrics and gynecology, cosmetic surgery, and cosmetic dermatology. We have partnerships with . Alongside supporting the provision of appropriate medical care and conducting joint research on new therapies, we recognize that addressing the management challenges of our partner medical institutions is also an important endeavor for us.

Medibase provides a cloud-based electronic medical record (EMR) service specifically tailored for the fields of cosmetic surgery and cosmetic dermatology. This EMR service facilitates the centralized management of medical information and enhances information security through cloud utilization. It significantly improves the operational efficiency of medical institutions. Additionally, the service includes features such as appointment scheduling and customer relationship management (CRM), which contribute to the improvement of the institution’s performance.

Through this Transaction, we aim to integrate Medibase’s advanced technology and expertise into our services for partner medical institutions. We also seek to leverage synergies within the shared domain of beauty related medical practices and explore new business opportunities to further advance our operations.

2. Medibase overview (as of September 12, 2024)

(1) Name	Medibase Co., Ltd
(2) Location	2-2-2 Umeda, Kita-ku, Osaka Hilton Plaza West Office Tower, 19th floor
(3) Title and name of representative	Noriya Yamaji, Representative Director
(4) Business	Development, operation and maintenance of Medibase, an electronic medical record system
(5) Capital	4 million yen
(6) Date of establishment	January 28, 2016

3. Future outlook

We assume that the impact of this Transaction on our company's performance for the current fiscal period will be minor, and we believe it will contribute to the improvement of our performance in the medium to long term. If there are any matters that need to be disclosed due to future developments, we will promptly provide information disclosure.

About CellSource Co., Ltd.

We specialize in advancing the industrialization of regenerative medicine, providing services such as processing adipose-derived stem cells, synovial-derived stem cells, and blood, as well as offering regulatory compliance support to medical institutions engaged in regenerative medicine. Operating under a Specific Cell Processing Manufacturing License (Facility Number: FA3160006) in accordance with the Act on the Safety of Regenerative Medicine, we have handled over 98,000 cell-related procedures. With a wealth of experience, we strive to offer reliable services to medical institutions and contribute to research and technological development.

Representative Director and CEO: Takashi Sawada

Representative Director and CXO: Masato Tsumamoto

Location: Shibuya Cast 11F, 1-23-21 Shibuya, Shibuya-ku, Tokyo

Website: <https://www.cellsource.co.jp/en/>

Note: This translation is for reference purposes only and is not guaranteed to be accurate or complete. In the event of any translation error or misunderstanding, the original Japanese version shall prevail.